The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
By J. Mcconnell, C. Roehrborn, O. Bautista, G. Andriole, C. Dixon, J. Kusek, H. Lepor, K. McVary, L. Nyberg, H. Clarke and 16 more. New England Journal of Medicine, 2003
1,883 citations recorded by the source corpus.
Subfields: Epidemiology, Psychiatry and Mental health, Urology
View Paper: https://www.semanticscholar.org/paper/7db6cc910119b03123fde480e102ac483c2d0328
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Oelke
- A. Bachmann
- C. Gratzke
- A. Descazeaud
- S. Madersbacher
- Mark Emberton
- J. de la Rosette
- S. Gravas
Citations in the corpus
- Update on AUA guideline on the management of benign prostatic hyperplasia. (2011, background): “Data from the long-term Medical Therapy of Prostatic Symptoms study suggest that while AUR and surgery rates were lower with doxazosin compared to placebo in the early years of follow-up, by five years, rates were similar in both groups.(4) The timelimited effect noted for doxazosin is likely a clas”
- EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. (2015, methodology): “In both the MTOPS and ALTESS studies, high baseline PVR was associated with an increased risk of symptom deterioration [53,54].”
- The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. (2010, result): “No significant difference was observed between combination therapy and dutasteride, which is concordant with other data [7].”
- EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013, methodology): “The MTOPS study found that the risk of long-term clinical progression (primarily due to increasing IPSS) was reduced by 66% with combined therapy (vs placebo) and to a greater extent than with either finasteride or doxazosin monotherapy (34% and 39%, respectively) [20].”